Cancer Biomarkers Market Size to Worth Around USD 61.37 Billion by 2033 | CAGR 14.62%

According to Vision Research Reports, the global cancer biomarkers market size was accounted for USD 15.68 billion in 2023 and it is increasing around USD 61.37 billion by 2033 with a CAGR of 14.62% from 2024 to 2033. Cancer biomarkers encompass a diverse array of molecules, genes, proteins, or other substances that indicate the presence of cancer or its progression. They offer valuable insights into the biological processes underlying cancer development, enabling early detection and targeted interventions. Biomarkers hold immense potential for revolutionizing cancer care by facilitating precision medicine approaches tailored to individual patients.

Certain factors driving market growth include increased cancer incidence globally and higher acceptance of cancer treatments in developing regions; a paradigm shift in healthcare from disease diagnosis to risk assessment or early diagnosis; and increased use of biomarkers in drug development. For instance, in the Cancer Facts & Figures 2022 data published by the American Cancer Society, there will be an estimated 1.9 million new cancer cases diagnosed in the United States (US) in 2022. Further, as per the GLOBOCAN 2020 report, the number of new cancer cases is expected to reach 24,044,406 by 2030, which shows an increasing prevalence of cancer around the globe. Thus, the increasing prevalence of cancer is expected to increase the demand for its early diagnosis as cancer treatment is much more cost-effective and successful at early stages. Hence, early diagnosis of cancer is expected to increase the adoption of cancer biomarkers which is expected to increase the market growth.

Moreover, strategic developments undertaken by market players are also anticipated to bolster the market's growth over the analysis period. For instance, in March 2022, Vela Diagnostics released new next-generation sequencing (NGS)-based panels to detect RNA and DNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens. The panels are focused (60 genes) and comprehensive (525 genes). The OncoKey SL 60 Plus Panel is a targeted pan-cancer gene panel, while the OncoKey SL 525 Plus Panel is a comprehensive pan-cancer gene panel. Similarly, collaboration, mergers, and acquisitions within the industry are expected to boost the market over the forecasted period. For instance, in June 2021, Medable teamed up with Aural Analytics to evaluate remote data capture and digital biomarkers in cancer patients as part of its cancer moonshot work. This partnership included tracking of speech and language-based information about motor, cognitive and respiratory functions combined with the analysis of objective outcomes data to increase the measurement of patients through digital biomarkers. This is expected to increase the constant monitoring to understand the disease, which would provide better treatment and thus is expected to increase the market growth.

Thus, due to the above factors, such as the increasing prevalence of cancer and product launches, the market is expected to see robust growth during the forecast period. However, the high cost of products and reimbursement issues restrain the market studied.

Key Pointers

  • In 2023, North America dominated the market, holding the largest share.
  • From 2024 to 2033, Asia-Pacific is expected to experience the highest growth rate.
  • The breast cancer segment accounted for the largest revenue share in 2023, based on type.
  • In terms of application, the diagnostics segment emerged as the leading force in the cancer biomarkers market.
  • The personalized medicine segment is projected to witness the fastest growth during the forecast period, based on application.
  • Among biomolecules, genetic biomarkers took the lead in the cancer biomarkers market.
  • The epigenetics segment is forecasted to experience the most rapid growth from 2024 to 2033, based on biomolecule type.

Get Sample Copy of Report@ https://www.visionresearchreports.com/report/sample/41256

Types of Cancer Biomarkers

  • Genetic Biomarkers: These biomarkers involve genetic mutations or alterations that are associated with the development or progression of cancer. Examples include mutations in the BRCA1 and BRCA2 genes in breast and ovarian cancer.
  • Epigenetic Biomarkers: Epigenetic changes, such as DNA methylation and histone modifications, can influence gene expression patterns in cancer cells. Aberrant epigenetic marks serve as biomarkers for various cancer types.
  • Protein Biomarkers: Protein biomarkers are specific proteins or protein signatures found in blood, tissue, or other bodily fluids that indicate the presence or characteristics of cancer. Examples include prostate-specific antigen (PSA) for prostate cancer and HER2/neu for breast cancer.
  • Circulating Tumor Cells (CTCs): CTCs are cancer cells that have detached from the primary tumor and entered the bloodstream. Detection and analysis of CTCs can provide valuable information about cancer metastasis and treatment response.
  • Imaging Biomarkers: Imaging techniques such as MRI, CT scans, and PET scans can reveal structural or functional changes associated with cancer. These imaging biomarkers aid in cancer diagnosis, staging, and treatment planning.
  • MicroRNA Biomarkers: MicroRNAs are small non-coding RNA molecules that regulate gene expression. Dysregulated expression of microRNAs has been linked to cancer development and progression, making them potential biomarkers for cancer diagnosis and prognosis.
  • Metabolomic Biomarkers: Metabolomics involves the study of small molecules or metabolites present in cells, tissues, or biofluids. Alterations in metabolic pathways associated with cancer can produce unique metabolomic signatures that serve as biomarkers for cancer detection and monitoring.

Applications of Cancer Biomarkers

  • Early Detection and Diagnosis: Cancer biomarkers facilitate early detection of malignancies, enabling timely intervention and improved prognosis. By detecting specific molecular changes associated with cancer development, biomarker-based tests can help identify cancer at its earliest stages when treatment is most effective.
  • Prognostic Assessment: Biomarkers provide valuable prognostic information by predicting disease progression, recurrence risk, and patient outcomes. By assessing the molecular characteristics of tumors, clinicians can stratify patients into different risk categories and tailor treatment strategies accordingly.
  • Treatment Selection and Monitoring: Biomarker-based assays guide therapeutic decision-making by identifying predictive markers associated with treatment response or resistance. By analyzing tumor biomarkers, clinicians can select the most appropriate treatment modalities, including chemotherapy, targeted therapy, immunotherapy, or combination regimens. Additionally, biomarkers are used to monitor treatment efficacy and disease progression over time, allowing for timely adjustments to therapy.
  • Predictive Biomarkers for Targeted Therapy: Certain biomarkers serve as predictive indicators of response to targeted therapies directed against specific molecular targets. For example, the presence of HER2/neu amplification in breast cancer predicts response to anti-HER2 therapies such as trastuzumab (Herceptin). Similarly, mutations in the EGFR gene are predictive of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).
  • Companion Diagnostics: Biomarker-based companion diagnostics play a crucial role in personalized medicine by matching patients with targeted therapies based on their molecular profiles. Companion diagnostic tests help identify patients who are most likely to benefit from a particular treatment and minimize unnecessary exposure to ineffective therapies or adverse side effects.
  • Minimal Residual Disease (MRD) Monitoring: Biomarkers are utilized for monitoring minimal residual disease (MRD) in cancer patients who have undergone treatment. MRD refers to the presence of residual cancer cells that may not be detectable by conventional imaging or clinical assessments. Biomarker-based MRD monitoring allows for early detection of disease recurrence and timely intervention to prevent disease progression.
  • Biomarker Discovery and Development: Biomarker research plays a vital role in identifying novel molecular targets for cancer detection, prognosis, and therapy. Through genome-wide profiling, proteomic analysis, and other high-throughput techniques, researchers continue to discover new biomarkers with diagnostic, prognostic, and predictive utility. These biomarkers undergo rigorous validation and clinical testing before being translated into clinical practice.

Global Cancer Biomarkers Market Dynamics:

Drivers

  • Increasing R&D activities Associated with Cancer Biomarkers: Increasing R&D efforts in cancer biomarkers are driving market growth. For example, Hitachi and Centre Léon Bérard cancer center collaborated in 2019 to establish the Hitachi Lyon Lab, focusing on improving cancer diagnosis and treatment efficiency. Their research includes identifying biomarkers related to treatment resistance using genomic data, aiding in predicting post-radiation treatment responses and prognoses. This surge in research, coupled with the high cancer burden, contributes to market expansion.
  • Rise in Product Developments Associated with Biomarkers: Additionally, strategic product developments by key market players are fueling market growth. Vela Diagnostics launched new next-generation sequencing (NGS)-based panels in 2022 to identify RNA and DNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens. These panels, covering 60 genes primarily and 525 genes comprehensively, enhance biomarker detection. Moreover, researchers at Clarkson University introduced protein biomarkers in 2022 for screening breast cancer in breast milk or blood serum. These biomarkers, targeting invasive ductal carcinoma (IDC), offer promising screening options, further stimulating market growth.

Opportunities

  • Increasing Cancer Cases: According to Globocan 2020 data, the U.K. reported approximately 457,960 new cancer cases, with breast, lung, colon, prostate, and skin cancer being the most common types detected. Italy recorded 415,269 new cancer cases and approximately 174,759 deaths. The rising number of cancer cases has led to widespread use of cancer biomarkers in research institutes and hospitals, a trend expected to continue growing significantly in the forecast period.
  • Growing Partnerships Between Market Players: The market has seen an uptick in partnerships between various organizations, driving growth. In 2021, for example, Medable teamed up with Aural Analytics to evaluate remote data capture and digital biomarkers in cancer patients as part of its cancer moonshot initiative. This collaboration focuses on monitoring speech and language-based indicators linked to motor, cognitive, and respiratory functions. By analyzing objective outcomes data, the partnership aims to enhance patient measurement through digital biomarkers, contributing to market growth.

Related Reports

Type Insights

In 2023, the breast cancer segment solidified its position as a dominant force in the cancer biomarkers market. According to the World Health Organization (WHO), breast cancer afflicted 2.3 million women globally in 2020, leading to 685,000 fatalities. Over the preceding five years, breast cancer was diagnosed in 7.8 million women, cementing its status as the most prevalent cancer worldwide. This surge in breast cancer cases is a primary driver behind the segment's growth.

Concurrently, the lung cancer segment emerged as the fastest-growing sector within the cancer biomarkers market in 2023. Predominantly affecting the elderly population, with most diagnoses occurring in individuals aged 65 and above, lung cancer has a relatively low incidence among those under 45 years old. The average age at diagnosis typically hovers around 70 years. Consequently, the expanding geriatric population plays a significant role in propelling the growth of this segment.

Application Insights

In 2023, the diagnostics segment emerged as the leading force in the cancer biomarkers market. Its dominance is driven by several factors, including the increased development of efficient and effective cancer biomarkers through oncology tests, along with growing government initiatives. These factors collectively contribute to the segment's growth during the forecast period.

Meanwhile, the personalized medicine segment stands out as the fastest-growing sector in the forecast period. This growth is fueled by heightened awareness among healthcare practitioners regarding cancer biomarkers and the growing demand for personalized medicines. Additionally, the streamlined approval process for diagnostic tests plays a significant role in driving this segment's growth, further bolstering the demand for cancer biomarkers.

Biomolecule Insights

In 2023, the genetic biomarkers segment emerged as the dominant force in the cancer biomarkers market. These biomarkers are widely utilized for their high efficiency and effectiveness, making them essential for cancer diagnosis and treatment. The extensive usage and efficacy of genetic biomarkers are key drivers propelling the growth of this segment.

Meanwhile, the epigenetics segment stands out as the fastest-growing sector over the forecast period. This growth is fueled by increasing research efforts aimed at developing novel biomarkers within the field of epigenetics. Additionally, collaborations between market players and pharmaceutical firms are further bolstering the growth of this segment, contributing to its rapid expansion.

Regional Insights

In 2023, North America emerged as the dominant player in the cancer biomarkers market, with the United States leading the region and holding a significant market share. This leadership is attributed to the presence of numerous market players dedicated to cancer biomarkers and substantial investments by the U.S. government in research and development efforts, fostering innovation. Additionally, the adoption of advanced technologies further drives market growth in North America.

North America is expected to hold a significant share of the cancer biomarkers market. Factors such as the increasing prevalence of cancer coupled with initiatives by key market players are expected to increase market growth over the forecast period. The United States has witnessed a considerable rise in the number of cancer patients. Breast cancer can occur both in men and women. However, it is mostly found among females, and the occurrence of male breast cancer is very rare. For instance, according to the data provided by Breastcancer.org, in March 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the United States, along with 51,400 new cases of non-invasive (in situ) breast cancer in 2022. Similarly, as per the Canadian Cancer Statistics 2021 released in November 2021, an estimated 229,200 Canadians were diagnosed with cancer in 2021. The increasing number of cancer cases is expected to increase the adoption of cancer biomarkers for diagnosis, which is expected to increase market growth over the forecast period.

The availability of funds from various organizations, such as the National Institute of Health, has provided the potential for researchers to invest more in the use of biomarkers in drug discovery, drug development, the detection of specific tumors, monitoring biological response to cancer therapy, and genetic studies for the identification of predisposed candidates for cancer.

Additionally, the high concentration of key players in North America, increasing United States Food and Drug Administration approvals strategic alliances, and high investment in research and development activities are expected to boost the market in the region. For instance, in April 2022, researchers at Clarkson University in New York discovered a set of protein biomarkers that could be used to screen for breast cancer in breast milk or blood serum. The biomarkers were discovered for a kind of cancer termed invasive ductal carcinoma (IDC), which is one of the most common types of breast cancer. The researchers claim, however, that their method might be applied to find biomarkers for different types of breast cancer as well.

Thus, due to the aforementioned factors, such as the high incidence rate of cancer cases and the launches by key market players, the cancer biomarkers market is expected to grow over the coming years in the North American region.

Meanwhile, the Asia-Pacific region is expected to experience the highest growth during the forecast period. The expansion of the cancer biomarkers market in this region is fueled by the increasing prevalence of cancer, driving demand for effective diagnostic and treatment solutions. Government funding for product development initiatives and growing awareness of cancer biomarkers among healthcare professionals and the public also contribute to market growth in Asia-Pacific.

Recent Development

  • In 2022, Abbott Laboratories launched Lingo, a bio-wearable for tracking body signals and improving health understanding. It provides continuous data, replacing periodic tests like finger pricks and breath readings.
  • Also in 2022, OncoDNA introduced the OncoDEEP kit. It enables NGS-equipped labs to conduct thorough biomarker testing and assist oncologists in customizing cancer treatments effectively.

Cancer Biomarkers Market Key Companies

  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Illumina Inc.
  • Bio-Rad Laboratories Inc.
  • Abbott Laboratories
  • Exact Sciences
  • Meso Scale Diagnostics LLC
  • Seegene Technologies Inc.
  • Siemens Healthineers

Cancer Biomarkers Market Segmentations:

By Type

  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Liver Cancer
  • Lung Cancer
  • Others

By Biomolecule

  • Genetic Biomarkers
  • Epigenetic Biomarkers
  • Metabolic Biomarkers
  • Proteomic Biomarkers
  • Others

By Application

  • Drug Discovery and Development
  • Diagnostics
  • Personalized Medicine
  • Others

By Profiling Technology

  • Omic Technologies
  • Imaging Technologies
  • Immunoassays
  • Cytogenetics-based Tests

By End User

  • Hospitals
  • Academic and Cancer Research Institutes
  • Ambulatory Surgical Centres
  • Diagnostic Laboratories

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Immediate Delivery Available, Get Full Access@ https://www.visionresearchreports.com/report/checkout/41256

Ask here for more details sales@visionresearchreports.com OR USA: +1 650 460 3308 IND: +91 87933 22019 Europe: +44 2080772818

 

Back to news